Skip to content
Canine PeptideResearch peptides

Peptides for Newfoundland hip dysplasia

The short answer

Newfoundlands carry an elevated predisposition to hip dysplasia. The compounds investigated for it are BPC-157, TB-500, GHK-Cu. At a typical Newfoundland weight of 45–68 kg (99–150 lb), this breed falls in the large / giant breed dosing class.

Hip dysplasia in Newfoundlands

Hip dysplasia is a developmental condition in which the femoral head and acetabulum do not fit together correctly. The resulting laxity grinds cartilage away over years, and the arthritis that follows is what most owners actually notice: difficulty rising, reluctance on stairs, a bunny-hopping gait, and loss of muscle over the hindquarters. Peptide research in this area is directed at the secondary consequences rather than the underlying joint geometry — no compound reshapes a hip. What the literature investigates is whether soft tissue repair and inflammatory modulation can slow cartilage degradation and improve comfort and mobility alongside conventional management.

Dosing at Newfoundland body weight

Calculated for a 57 kg (126 lb) dog — the midpoint of the typical range for this breed.

CompoundDose at 57 kgFrequencyEvidence
BPC-157114–570 mcgOnce dailyEmerging evidence
TB-5005.7–14.3 mgLoading 1-2x weekly, then half dose weeklyEmerging evidence
GHK-Cu1.5-2 mg per day injectable, or topical twice dailyDaily (injectable) / twice daily (topical)Emerging evidence

Weigh your dog rather than using a breed average — an individual Newfoundland can sit well outside the typical range. Use the dose calculator for an exact figure.

Common questions

What peptides are used for hip dysplasia in Newfoundlands?+

BPC-157, TB-500, GHK-Cu are investigated for hip dysplasia. No breed-specific pharmacological restriction is established for Newfoundlands among these compounds.

How much should a Newfoundland be given?+

Newfoundlands typically weigh 45–68 kg (99–150 lb), placing them in the large / giant breed class. BPC-157: approximately 114–570 mcg at 57 kg. TB-500: approximately 5.7–14.3 mg at 57 kg. Weigh your dog rather than relying on a breed average.

Are Newfoundlands more prone to hip dysplasia?+

Yes. Newfoundlands carry an elevated predisposition to hip dysplasia. A malformed hip joint that leads to instability, cartilage wear, and secondary arthritis, most common in large and giant breeds.

References

  1. 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
  2. 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
  3. 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
  4. 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
  5. 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
  6. 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
  7. 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
  8. 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
  9. 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
  10. 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
  11. 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
  12. 12.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
  13. 13.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
  14. 14.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
  15. 15.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520

Other conditions Newfoundlands are predisposed to: Cranial cruciate ligament (CCL) tear, Osteoarthritis.

Where to source research peptides

Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.

Visit Pet & Peps Research →How to evaluate a supplier

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.